Gene modification can encourage T cell growth, improving cancer treatment's success rate
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...
FierceBiotech2d
Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach
Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...
Lupus Foundation of America6d
Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial
The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...
Pharm Exec4d
FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
CARGO Therapeutics, Inc. Being Investigated on Behalf of CARGO Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO ...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...
ascopubs.org10d
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...
BioWorld9d
Cargo stops firi-cel phase II on safety, durability; stock sinks
In a devastating blow to the company and large B-cell lymphoma patients relapsed or refractory to CD19 CAR T-cell therapy, Cargo Therapeutics Inc. terminated the phase II study of its lead CD22 cell ...
MedCity News10d
Safety Risk Sinks Cargo Therapeutics’ Cancer Cell Therapy Prospect, Leading to 50% Staff Cut
Firi-cel was being tested in a potentially pivotal Phase 2 trial enrolling patients with relapsed or refractory large B-cell lymphoma (LBCL) that had progressed following treatment with a CD19 ...
CAR T-Cell Therapy Market to Reach US$ 22.2 Billion By 2032 | Astute Analytica
CAR T-Cell therapy market growth is propelled by revolutionary results in treating certain blood cancers.New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is ...